# US 12,599,565 B2 · Stable benzimidazole formulation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,565 B2 - Document ID: US12599565B2 - Status: Granted - Kind: B2 - Application number: 17/501,237 - Filed: 2021-10-14 - Published: 2022-02-03 - Granted: 2026-04-14 - Earliest claimed: 2008-05-06 - Assignees: Dexcel Pharma Technologies Ltd. - Applicants: Dexcel Pharma Technologies Ltd. - Inventors: Adel Penhasi; Avi Avramoff; Maxim Gomberg; Valerie Azoulay - Web page: https://patentgrep.com/patent/US12599565B2 ## CPC - A61K 9/2095: {Tabletting processes} - A61K 9/282: {Organic compounds, e.g. fats} - A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} - A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)} - A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An omeprazole delayed release tablet comprises a core and an enteric coating over the core. The core consists essentially of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate. The enteric coating over the core consists essentially of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, and less than 500 ppm of residual ammonium hydroxide. ## Claims ### Claim 1 An omeprazole delayed release tablet consisting of: a core consisting of omeprazole, lactose, sodium starch glycolate, sodium stearate, and sodium stearyl fumarate; and an enteric coating over the core consisting of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide; wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons. ### Claim 2 An omeprazole delayed release tablet consisting of: a core and an enteric coating over the core, wherein the core consists of about: 20 mg omeprazole, 203 mg lactose monohydrate, 10 mg sodium starch glycolate, 10 mg sodium stearate, and 7 mg sodium stearyl fumarate, wherein the enteric coating consists of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide; wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons. ### Claim 3 An omeprazole delayed release tablet consisting of: a core and an enteric coating over the core, wherein the core consists of about: 8 weight % omeprazole, 81.2 weight % lactose monohydrate, 4 weight % sodium starch glycolate, 4 weight % sodium stearate, and 2.8 weight % sodium stearyl fumarate by weight percent of the core, wherein the enteric coating consists of hydroxypropyl methyl cellulose (HPMC) acetate succinate, triethyl citrate, sodium lauryl sulfate, talc, monoethanol amine, a coloring agent and less than 500 ppm of residual ammonium hydroxide by weight percent of the enteric coating; wherein said monoethanol amine is prepared from an aqueous solution and is present in the coating in an amount of 1.195 weight %, 1.251 weight %, 1.28 weight %, 1.282 weight %, 1.325 weight %, 1.35 weight %, 1.360 weight %, 1.368 weight %, 1.388 weight %, 1.396 weight %, 1.44 weight %, 1.477 weight %, 1.59 weight %, or 1.75 weight % to reduce residual ammonium hydroxide in said tablet to a lower amount for toxicity/safety reasons. ### Claim 4 (depends on 1) The omeprazole delayed release tablet of claim 1, wherein the omeprazole is present in the core in an amount of 20 mg. ### Claim 5 (depends on 1) The omeprazole delayed release tablet of claim 1, wherein the omeprazole is present in the core in an amount of about 8 weight %. ### Claim 6 (depends on 2) The omeprazole delayed release tablet of claim 2, wherein the HPMC acetate succinate is present in the coating in an amount of 32 mg, the triethyl citrate is present in the coating in an amount of 4.5 mg, the sodium lauryl sulfate is present in the coating in an amount of 0.5 mg, the talc is present in the coating in an amount of 8.14 mg, and the coloring agent is present in the coating in an amount of 10.8 mg. ### Claim 7 (depends on 3) The omeprazole delayed release tablet of claim 3, wherein the HPMC acetate succinate is present in an amount of 56.14 weight % of the coating, the triethyl citrate is present in an amount of 7.89 weight % of the coating, the sodium lauryl sulfate is present in an amount of 0.88 weight % of the coating, the talc is present in an amount of 14.28 weight % of the coating, and the coloring agent is present in an amount of 18.95 weight % of the coating. ### Claim 8 (depends on 1) The omeprazole delayed release tablet of claim 1, wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %. ### Claim 9 (depends on 1) The omeprazole delayed release tablet of claim 1, wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %. ### Claim 10 (depends on 2) The omeprazole delayed release tablet of claim 2, wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %. ### Claim 11 (depends on 2) The omeprazole delayed release tablet of claim 2, wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %. ### Claim 12 (depends on 3) The omeprazole delayed release tablet of claim 3, wherein the monoethanol amine is present in the coating in an amount of 1.195 weight %. ### Claim 13 (depends on 3) The omeprazole delayed release tablet of claim 3, wherein the monoethanol amine is present in the coating in an amount of 1.75 weight %.